Elixir Medical Corporation

Congratulations to Dr. Julia Mascherbauer, Dr. Paul Vock and the team at St. Pölten University on your first #DynamX implant in the BIO-RESTORE post-market registry.   The team treated a 67-year-old patient with a tortuous proximal right coronary artery (RCA).   Thank you to our local, exclusive Austrian partner, NOVOMED Handels-GesmbH, for supporting the case.    #Innovation #Cardiology #leavetherightthingbehind #bioadaptor   CE marked. Not for sale in the U.S.   PMN 1992 Rev A

DESyne BDS Plus Trial: FIM Outcomes of Triple-Drug Antithrombotic DES   Discussing the findings and implications of DESyne BDS Plus study. The conversation delves into the study's design, key results at 12-month follow-up and future potential impact on clinical practice. Balancing ischaemic and bleeding risk with oral anti-thrombotic drugs remains a significant clinical challenge, especially in patients who are at high thrombotic risk and high bleeding risk. 12-month results from DESyne BDS Plus RCT demonstrate the safety and effectiveness of site specific anti-thrombotic drug therapy (TRx) with significantly lower TLF rate (2.1% vs. 9.3%, p=0.030) vs the contemporary DES group in complex patients.1 The interview highlights how the RCT findings could potentially impact patient outcomes post-intervention and influence clinical practice. Discutindo os achados e as implicações do estudo DESyne BDS Plus. A conversa explora o desenho do estudo, os principais resultados no seguimento de 12 meses e o potencial impacto futuro na prática clínica. Equilibrar o risco isquêmico e o risco de sangramento com medicamentos antitrombóticos orais continua sendo um desafio clínico significativo, especialmente em pacientes com alto risco trombótico e alto risco de sangramento. Os resultados de 12 meses do RCT DESyne BDS Plus demonstram a segurança e a eficácia da terapia antitrombótica específica para o local (TRx) com uma taxa de TLF significativamente menor (2,1% vs. 9,3%, p=0,030) em comparação ao grupo contemporâneo de DES em pacientes complexos. A entrevista destaca como os achados do RCT podem potencialmente impactar os desfechos dos pacientes após a intervenção e influenciar a prática clínica.

Watch Dr. Mirvat Alasnag as she offers her perspective on the BIOADAPTOR RCT two-year data and the impact the results could have on her practice and the future of PCI.   #Innovation #Cardiology #Bioadaptor   CE marked. Not for sale in the U.S.   PMN 1994 REV A

💡 Hear from Dr. Santoso Teguh as he shares his experience with the #DynamX bioadaptor and his observations on the impact it has on patient outcomes in his practice. View the full video here: https://lnkd.in/eWJnqqrj CE marked. Not for sale in the U.S.    #Cardiovascular #Medtech #Innovation #leavetherightthingbehind   PMN 1946 Rev A

We are very excited to share that Curaçao Medical Center (CMC) now offers bioadaptive angioplasty with the DynamX bioadaptor, a revolutionary innovation in percutaneous coronary intervention (PCI), to patients in the Caribbean Islands. The DynamX bioadaptor has shown to restore artery motion and function resulting in hemodynamic modulation and improved health outcomes compared to drug-eluting stents.¹ ² Congratulations to the entire CMC Cathlab team, and in particular to Dr. Arthur Liqui Lung, Cardiology Medical Director, and Dr. Jose Torres and Dr. José Navarro. #DynamX ¹ Saito S. et al. 12-month clinical and imaging data from the multi-centre, international, BIOADAPTOR RCT. eClinicalMedicine Lancet. 2023 ² Presented by Shigeru Saito, MD, at EuroPCR 2024

We were honored to participate in a live case session at MyLIVE 2024, broadcast from the Institut Jantung Negara Malaysia (IJN), the largest heart hospital in Malaysia. The session featured the innovative bioadaptive angioplasty technique to treat complex, diffuse and tortuous LAD disease. The case selection was supported by clinical study results that show restoration of hemodynamic modulation and improved clinical outcomes, including significant reduction in TLF rate (78% reduction at 2 years) in LAD lesions, following bioadaptive angioplasty with DynamX bioadaptors.¹ ² This event also showcased how DynamX bioadaptor technology can effectively restore vessel function and angulation, particularly in challenging LAD lesions. A special thank you to our esteemed operators, Dr. Tamil Selvan Muthusamy from Cardiac Vascular Sentral Kuala Lumpur (CVSKL) and Dr. Hafidz bin Abd Hadi from IJN. ¹ Saito S, et al. BIOADAPTOR RCT 12-month clinical and imaging data. eClinicalMedicine Lancet 2023 ² Saito S. BIOADAPTOR RCT 2-Year Results. Presented at EuroPCR 2024 PMN 1977 Rev A

📣 You don’t want to miss this! Watch the full video of Dr. Bambang Budiono as he highlights the #DynamX bioadaptor’s unique mechanism of action and how it’s designed to help restore hemodynamic modulation of the vessels: https://lnkd.in/e6HQNhkZ    CE marked. Not for sale in the U.S.    #Cardiovascular #Medtech #Innovation #leavetherightthingbehind   PMN 1948 Rev A

Heading to #ESC2024? Join us as we announce late-breaking, one-year primary outcomes from the 2,400-patient INFINITY-SWEDEHEART clinical trial evaluating #DynamX Coronary Bioadaptor System compared to contemporary DES.    The results will be presented by Dr. David Erlinge in a Hot Line session  on Monday, September 2, 2024.    Stefan James   Read more here: https://lnkd.in/eJnVhvd4   #Medtech #Innovation #Cardiology   CE marked. Not for sale in the U.S.    PMN 1895 REV A

𝗧𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗣𝗲𝗿𝗰𝘂𝘁𝗮𝗻𝗲𝗼𝘂𝘀 𝗖𝗼𝗿𝗼𝗻𝗮𝗿𝘆 𝗜𝗻𝘁𝗲𝗿𝘃𝗲𝗻𝘁𝗶𝗼𝗻𝘀: 𝗕𝗶𝗼𝗮𝗱𝗮𝗽𝘁𝗶𝘃𝗲 𝗔𝗻𝗴𝗶𝗼𝗽𝗹𝗮𝘀𝘁𝘆 CVSKL now offers bioadaptive angioplasty to treat coronary artery disease (CAD). This innovative therapy not only opens blocked arteries like traditional angioplasty but also restores natural vessel function using the DynamX®️ bioadaptor, a novel coronary implant. The DynamX®️ bioadaptor uncages after healing, allowing arteries to pulse and function more naturally, reducing risks of heart attacks and repeat procedures due to secondary adverse events. Clinical studies showed significant benefits such as reduction in plaque volume and increased blood flow in the vessel compared to a standard stent. We are pleased to be one of the few centres in Malaysia to offer this treatment. This innovation will help patients, especially younger ones, reclaim an active lifestyle with better long-term outcomes. For more information: https://lnkd.in/gTEtgsXd. Patients can undergo this procedure under the expert care of CVSKL’s consultant cardiologists Dato' Dr. Tamil Selvan, Dr. Choo Gim Hooi, Datuk Dr. Rosli Mohd Ali, Dr. Al Fazir Omar and Dr. Jayakhanthan Kolanthaivelu. To book an appointment, contact: 📞 Call: +603 2276 7000 📱 WhatsApp: +603 2276 7002 📧 Email: [email protected] #CVSKL #HeartHospital #KualaLumpur #Cardiologist #Doctor #Health #CAD #Angioplasty #DrTamil #DrChooGimHooi #DrRosli #DrAlFazir #DrJayakhanthan #HeartAttack #KnowYourOptions

📣 Have you heard? #DynamX Coronary Bioadaptor System is available in leading innovation centers around the world! Introducing our latest video series featuring some of our expert users as they share why they offer the bioadaptor to patients! First up, Dr. Michał Hawranek, from the Silesian Centre for Heart Disease Zabrze in Poland, shares his perspective on DynamX BIOADAPTOR RCT data and what this could mean for his patients. Watch the full video here: https://lnkd.in/ezy23QVn CE marked. Not for sale in the U.S. #Cardiovascular #Medtech #Innovation #leavetherightthingbehind   PMN 1944 Rev A